EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory Trial

Noeul Kang, Min-Gyu Kang, Seung Eun Lee, Sung-Yoon Kang, Eun-Jung Jo, Ji Ho Lee, Sae-Hoon Kim, Joon-Woo Bahn, Byung-Jae Lee, Woo-Jung Song iD

Lung · 2025-12 · 203 (1)

DOI: 10.1007/s00408-025-00815-5 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Lung, online erschienen am 29.04.2025. Verfasst von Noeul Kang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Esomeprazole, Gastroesophageal Reflux, Cough, Proton Pump Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daewoong Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Potassium-competitive acid blockers (P-CABs) are a newer class of acid suppressants with convenient dosing and a rapid onset of action, while showing efficacy comparable to proton pump inhibitors (PPIs) in treating peptic symptoms of gastroesophageal reflux disease (GERD). This study aimed to assess the effect of P-CABs on GERD-related chronic cough. METHODS: This randomized, double-blind, active-controlled, exploratory trial evaluated adults with chronic cough (≥ 8 weeks) and a recent physician diagnosis of GERD or peptic symptoms (< 1 month). Participants were randomized (1:1) to receive either fexuprazan 40 mg or esomeprazole 40 mg (PPI) once daily for eight weeks, along with matched placebos. The primary endpoint was the change in Leicester Cough Questionnaire (LCQ) score from baseline. Secondary endpoints included changes in the cough severity Numerical Rating Scale (NRS) and Reflux Disease Questionnaire (RDQ) scores. Safety was evaluated through monitoring adverse events. RESULTS: Of the 190 subjects recruited, 161 met the selection criteria and were randomized, and 146 completed the trial. The participants were predominantly female (74.3%, mean age 39 ± 12 years). After 8 weeks of treatment, cough-related quality of life improved significantly, with comparable LCQ scores change between the groups (fexuprazan: 4.9 ± 4.0 vs. esomeprazole: 5.3 ± 3.8, p = 0.558). Changes in cough severity NRS and RDQ scores were also similar between the groups. Adverse events were comparable and consisted mostly of mild symptoms. CONCLUSION: These findings support the potential of P-CABs as a promising alternative to PPIs for patients with chronic cough requiring acid-suppressive therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EsomeprazoleGastroesophageal RefluxCoughProton Pump InhibitorsHumansDouble-Blind MethodFemaleMaleMiddle AgedAdultChronic DiseaseTreatment OutcomeSeverity of Illness IndexAgedChronic CoughPyrrolesSulfonamides

Stichwörter der Autor:innen

Chronic coughGastroesophageal reflux diseasePotassium-competitive acid blockersProton pump inhibitorsQuality of life

Substanzen

EsomeprazoleProton Pump Inhibitors1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanaminePyrrolesSulfonamides

Autor:innen und Institutionen

  • Division of Allergy, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Departmemt of Internal Medicine, Chungbuk National University Hospital, Chungbuk National College of Medicine, Cheongju, Korea.
  • Department of Internal Medicine, School of Medicine, Pusan National University, Pusan National University Yangsan Hospital, Yangsan, Korea.
  • Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
  • Department of Internal Medicine, Pusan National University College of Medicine, Busan, Korea.
  • Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.

ORCID-Profile: Woo-Jung Song

Förderung

  • Daewoong Pharmaceutical Co., Ltd.

Zitieren

APA

Kang, N., Kang, M. G., Lee, S. E., Kang, S. Y., Jo, E. J., Lee, J. H., Kim, S. H., Bahn, J. W., Lee, B. J., & Song, W. J. (2025). Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory Trial. Lung, 203(1). https://doi.org/10.1007/s00408-025-00815-5

Vancouver

Kang N, Kang MG, Lee SE, Kang SY, Jo EJ, Lee JH, et al. Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory Trial. Lung. 2025;203(1). doi:10.1007/s00408-025-00815-5

BibTeX
@article{Kang2025,
  author = {Kang, Noeul and Kang, Min-Gyu and Lee, Seung Eun and Kang, Sung-Yoon and Jo, Eun-Jung and Lee, Ji Ho and Kim, Sae-Hoon and Bahn, Joon-Woo and Lee, Byung-Jae and Song, Woo-Jung},
  title = {Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory Trial},
  journal = {Lung},
  year = {2025},
  volume = {203},
  number = {1},
  doi = {10.1007/s00408-025-00815-5}
}
Kostenlos starten →